Search

Your search keyword '"Protein Kinase Inhibitors administration & dosage"' showing total 5,952 results

Search Constraints

Start Over You searched for: Descriptor "Protein Kinase Inhibitors administration & dosage" Remove constraint Descriptor: "Protein Kinase Inhibitors administration & dosage"
5,952 results on '"Protein Kinase Inhibitors administration & dosage"'

Search Results

1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis.

2. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.

3. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

4. Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real-world data.

5. Aderenza e persistenza come indicatori di esito in tempo reale dei trattamenti farmacologici oncoematologici e il caso degli anti-EGFR in prima linea nello NSCLC.

6. Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When.

7. Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study.

8. Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects.

9. New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies.

10. Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management.

11. Clinical Pharmacology of Asciminib: A Review.

12. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.

13. Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma.

14. Preparation of dual drug-loaded polymer nanoconjugate to enhance treatment efficacy for ovarian cancer cells.

15. Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.

16. Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.

17. Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.

18. Pharmacokinetics, mass balance, and metabolism of [ 14 C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects.

19. The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C Study.

20. Meta-analyses of phase I dose-finding studies: Application for the development of protein kinase inhibitors in oncology.

21. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.

22. Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study.

23. Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors.

24. ASO Author Reflections: Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.

25. Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery - A Modeling Approach.

26. Effect of peripheral blood lymphocyte count on the efficacy of immunotherapy combined with TKI in the treatment of advanced liver cancer.

27. Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474.

28. Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.

29. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC.

30. Resistant Vitiligo Treated with Tofacitinib and Sustained Repigmentation after Discontinuation.

31. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.

32. Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer.

33. Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling.

34. Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.

35. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.

36. Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study.

37. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.

38. Tofacitinib for child-onset systemic lupus erythematosus.

39. Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study.

40. Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.

41. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.

42. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.

43. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.

44. Preformulation evaluation of selumetinib for topical application: skin distribution and photodegradation analysis using MALDI imaging and LC-MS/MS.

45. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia.

46. Durable efficacy with fixed-duration BTKi and venetoclax for CLL.

47. First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial.

48. Cobb syndrome effectively treated with trametinib.

49. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

50. Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).

Catalog

Books, media, physical & digital resources